These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
315 related items for PubMed ID: 6230470
1. [Recent advances in hypoxic cell radiosensitizer]. Ono K, Takahashi M, Nishidai T, Shibamoto Y, Abe M. Gan No Rinsho; 1983 Oct; 29(13):1608-12. PubMed ID: 6230470 [Abstract] [Full Text] [Related]
2. Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors. Ono K, Takahashi M, Nishidai T, Dodo Y, Shibamoto Y, Hiraoka M, Yukawa Y, Abe M. Radiat Med; 1984 Oct; 2(1):71-5. PubMed ID: 6242712 [Abstract] [Full Text] [Related]
3. [The effect of diethyl maleate (DEM) on the radiosensitization by misonidazole (MISO) in experimental animal tumors]. Ono K, Takahashi M, Nishidai T, Dodo Y, Abe M. Nihon Igaku Hoshasen Gakkai Zasshi; 1984 Mar 25; 44(3):517-22. PubMed ID: 6462898 [No Abstract] [Full Text] [Related]
4. The radiosensitizing effects of misonidazole (MISO) in combination with diethyl maleate (DEM) in mouse mammary tumors. Ono K, Komuro C, Nishidai T, Shibamoto Y, Dodo Y, Takahashi M, Abe M, Shrieve DC. Int J Radiat Oncol Biol Phys; 1986 Oct 25; 12(10):1843-7. PubMed ID: 3759535 [Abstract] [Full Text] [Related]
5. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508. Yu NY, Brown JM. Int J Radiat Oncol Biol Phys; 1984 Aug 25; 10(8):1265-9. PubMed ID: 6236185 [Abstract] [Full Text] [Related]
6. A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170. Sasai K, Shibamoto Y, Takahashi M, Abe M, Wang J, Zhou L, Nishimoto S, Kagiya T. Jpn J Cancer Res; 1989 Nov 25; 80(11):1113-8. PubMed ID: 2532634 [Abstract] [Full Text] [Related]
7. Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors. Wallen CA, Moore SK, Wheeler KT. Int J Radiat Oncol Biol Phys; 1992 Nov 25; 22(4):727-30. PubMed ID: 1531976 [Abstract] [Full Text] [Related]
8. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration. Murayama C, Suzuki A, Sato C, Tanabe Y, Miyata Y, Shoji T, Suzuki T, Sakaguchi M, Mori T. Int J Radiat Oncol Biol Phys; 1992 Nov 25; 22(3):557-60. PubMed ID: 1531214 [Abstract] [Full Text] [Related]
9. Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma. Herman TS, Teicher BA, Holden SA, Pfeffer MR, Jones SM. Cancer Res; 1990 May 01; 50(9):2734-40. PubMed ID: 2139359 [Abstract] [Full Text] [Related]
10. [Present status of radiation sensitizers--hypoxic cell radiosensitizer]. Murayama C, Mori T. Gan To Kagaku Ryoho; 1989 Jun 01; 16(6):2135-41. PubMed ID: 2660744 [Abstract] [Full Text] [Related]
11. KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics. Sasai K, Shibamoto Y, Takahashi M, Zhou L, Hori H, Nagasawa H, Shibata T, Inayama S, Abe M. Cancer Chemother Pharmacol; 1990 Jun 01; 26(2):112-6. PubMed ID: 2140730 [Abstract] [Full Text] [Related]
18. In vivo radiosensitizing effect of nitroimidazole derivative KIN-804. Tada T, Nakajima T, Onoyama Y, Murayama C, Mori T, Nagasawa H, Hori H, Inayama S. Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):601-5. PubMed ID: 8005823 [Abstract] [Full Text] [Related]
19. Radiosensitizing effect of misonidazole in combination with an inhibitor of glutathione synthesis in murine tumors. Ono K, Komuro C, Nishidai T, Shibamoto Y, Tsutsui K, Takahashi M, Abe M. Int J Radiat Oncol Biol Phys; 1986 Sep 15; 12(9):1661-6. PubMed ID: 3759592 [Abstract] [Full Text] [Related]
20. [Radiosensitizer: hypoxic cell radiosensitizer]. Mori T. Gan To Kagaku Ryoho; 1989 Apr 15; 16(4 Pt 2-2):1399-404. PubMed ID: 2525001 [Abstract] [Full Text] [Related] Page: [Next] [New Search]